The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Categorizing subsets of T-cell lymphoma to improve trial design and treatment approaches
In this video, Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explains how categorizing subsets of T-cell lymphoma can improve clinical trial design and approaches to treatment. Dr Iyer first discusses some novel ways in which T-cell malignancies are being assessed, and further highlights novel immunohistochemistry approaches that are being used to move the field forward. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE
